Skip to content

The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island.

The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07090629
Acronym
EPICAC-RUN
Enrollment
126
Registered
2025-07-29
Start date
2024-05-06
Completion date
2025-03-21
Last updated
2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, High Cholesterol, Lipodystrophy, Familial Partial

Keywords

coronary calcium score, epicardial adipose tissue, cardiovascular risk scoring, lipodystrophy

Brief summary

The goal of this retrospective study is to see whether patients with familial partial type 2 lipodystrophy, who are at high cardiovascular risk present a higher volume of visceral epicardial adipose tissue than other patients without familial partial lipodystrophy who were assessed for their cardiovascular risk using coronary artery calcification scoring between 2016 and 2024.

Detailed description

Coronary artery calcification and clinical cardiovascular risk scoring are insufficient for patients with Familial Partial Lipodystrophy Part 2 (FPLD2), who often develop cardiovascular events before 40 and are insulin resistant. Epicardial adipose tissue volume could be a new, earlier marker of interest for these patients related to inflammation and atherosclerosis. The investigators retrospectively included high cardiovascular risk patients from 2016 to 2023 who had benefited from coronary artery calcification and clinical risk scoring at the University Hospital of La Réunion with Familial Partial Lipodystrophy Type 2 or controls and paired them for age, sex and body mass index. Epicardial adipose tissue volume was measured on the same tododensitometry as the CAC scoring, using a semi, automated technique that had been validated with deep learning at the Univeristy Hospital of Aix-Marseille.

Interventions

OTHEREpicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring

Epicardial adipose tissue measurement

Sponsors

Aix Marseille Université
CollaboratorOTHER
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
CollaboratorOTHER
Centre Hospitalier Universitaire de la Réunion
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients who received a check-up for hypercholesterolemia, obesity or diabetes including a CT scan to measure the coronary calcium score at the CHU de La Réunion between 2016 and 2023

Exclusion criteria

None

Design outcomes

Primary

MeasureTime frameDescription
Epicardial adipose tissue volumeat inclusionin mL

Countries

Reunion

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026